Microbiology and Treatment Outcome of Acute Exacerbation of Bronchiectasis in Hong Kong

Recruiting

• Conditions: Bronchiectasis

• Registration Number: NCT05112055
• Lead Sponsor: Pamela Youde Nethersole Eastern Hospital

Brief Summary

Bronchiectasis is a common disease worldwide with a high burden on healthcare resources. In Hong Kong (HK), local microbiological and clinical data regarding acute exacerbation of bronchiectasis (AEB) is lacking, in particular the frequency of pseudomonas aeruginosa (PA) in AEB is yet to be elucidated. A better understanding of the microbiology of AEB will provide evidence for judicious use of appropriate antibiotics in patients hospitalized for AEB to facilitate treatment and discharge.

This study aims to

1. elucidate the microbiology of AEB using both traditional culture and newer molecular multiplex methods,

2. identify factors associated with PA infection, and

3. describe the management and treatment outcome of AEB in HK

Detailed Description

Bronchiectasis is a common disease worldwide with a high burden on healthcare resources. In Hong Kong (HK), bronchiectasis ranked 5th highest as a cause of respiratory mortality, was the 6th highest reason for respiratory inpatient bed-days and was the 7th highest cause of respiratory hospitalization in Hong Kong in 2005.

Local microbiological and clinical data regarding acute exacerbation of bronchiectasis (AEB) is lacking, in particular the frequency of pseudomonas aeruginosa (PA) in AEB is yet to be elucidated. Traditional respiratory specimen takes time and lack sensitivity, a newer multiplex molecular method may be beneficial in improving sensitivity and reducing turnover time to detect pathogens involved in AEB. A better understanding of the microbiology of AEB will provide evidence for judicious use of appropriate antibiotics in patients hospitalized for AEB to facilitate treatment and discharge.

This study aims to

1. elucidate the microbiology of AEB using both traditional culture and newer molecular multiplex methods,

2. identify factors associated with PA infection, and

3. describe the management and treatment outcome of AEB in HK

Study Timeline

• Study First Submitted: 2021-10-08
• Study First Submitted QC: 2021-10-27
• Study First Posted: 2021-11-08
• Study Start: 2021-12-02
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-02
• Last Update Posted: 2024-04-03
• Primary Completion: 2025-02-28
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Microbiology	1 month	Frequency of pseudomonas aeruginosa (PA) and non-PA infection
Risk factors for PA infection	1 month	Risk factors for PA infection

Secondary Outcome Measures

Name	Time	Method
Antibiotics use	1 month	Length of antibiotics use (days)
Mortality	12 months	Rate of all-cause mortality in 1 year
Length of stay	1 month	Length of hospital stay for AEB (days)
Recurrent exacerbation	12 months	Frequency of recurrent exacerbation

Trial Locations

Locations (1)

Charles Wong; 🇭🇰 Hong Kong, Other, Hong Kong